VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical milestone.

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.